Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.


Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by Reaxense.


The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.


We use our state-of-the-art dedicated workflow for designing focused libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.


Our library stands out due to several important features:


  • The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.

  • Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.

  • Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.

  • Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.


PARTNER
Receptor.AI
 
UPACC
P04083

UPID:
ANXA1_HUMAN

ALTERNATIVE NAMES:
Annexin I; Annexin-1; Calpactin II; Calpactin-2; Chromobindin-9; Lipocortin I; Phospholipase A2 inhibitory protein; p35

ALTERNATIVE UPACC:
P04083; B5BU38

BACKGROUND:
Annexin A1, known by various names including Calpactin II and Phospholipase A2 inhibitory protein, is integral to the innate immune system. It regulates the inflammatory process, aids in glucocorticoid-mediated inflammatory response down-regulation, and supports the adaptive immune response. Annexin A1's ability to bind calcium and interact with phospholipid membranes plays a key role in phagocytosis and the formation of phagocytic cups.

THERAPEUTIC SIGNIFICANCE:
The exploration of Annexin A1's functions offers promising avenues for therapeutic intervention. Its critical role in immune response regulation and inflammation control makes it a compelling target for drug discovery efforts aimed at treating a range of immune-mediated and inflammatory diseases.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.